Neuronostics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 20

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $533K

  • Investors
  • 18

Neuronostics General Information

Description

Developer of neurological diagnosis software designed to improve the accuracy and speed of epilepsy detection. The company's software uses mathematical modelling and computational neuroscience to analyze routine electroencephalogram data for hidden digital biomarkers, enabling clinicians to receive objective decision-support reports and identify seizure risks even when traditional clinical recordings appear normal.

Contact Information

Website
www.neuronostics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Science Creates
  • Midland Road
  • Bristol BS2 0NS
  • England, United Kingdom
+44 0117
Primary Industry
Decision/Risk Analysis
Vertical(s)
Digital Health, Artificial Intelligence & Machine Learning, HealthTech
Corporate Office
  • Science Creates
  • Midland Road
  • Bristol BS2 0NS
  • England, United Kingdom
+44 0117

Neuronostics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neuronostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Grant 30-Jun-2026 $533K Completed Generating Revenue
12. Later Stage VC 20-Mar-2026 Completed Generating Revenue
11. Grant 02-Oct-2024 Completed Clinical Trials - Phase 3
10. Later Stage VC 19-Mar-2024 Completed Clinical Trials - Phase 3
9. Seed Round 04-Oct-2023 Completed Clinical Trials - Phase 2
8. Accelerator/Incubator 01-Apr-2021 Completed Clinical Trials - Phase 2
7. Seed Round 27-Mar-2021 Completed Clinical Trials - Phase 2
6. Grant 01-Jun-2017 Completed Pre-Clinical Trials
5. Accelerator/Incubator 01-Jan-2021 Completed Clinical Trials - Phase 2
4. Grant 10-Sep-2020 $1.98M Completed Clinical Trials - Phase 2
To view Neuronostics’s complete valuation and funding history, request access »

Neuronostics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Ordinary
Ordinary
Ordinary
A Ordinary
Ordinary 71,916 $0.000134 $3.73 $3.73 1x $3.73 2.78%
Ordinary 271,800 $0.000134 $2.36 $2.36 1x $2.36 10.51%
To view Neuronostics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Neuronostics Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • 4

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

Neuronostics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4547104-A1 Method and system for estimating dynamic seizure likelihood Pending 01-Jul-2022
GB-202209730-D0 Method and system for estimating dynamic seizure likelihood Pending 01-Jul-2022
GB-2620384-A Method and system for estimating dynamic seizure likelihood Pending 01-Jul-2022
US-20250380897-A1 Method and system for estimating dynamic seizure likelihood Pending 01-Jul-2022
WO-2024003419-A1 Method and system for estimating dynamic seizure likelihood Inactive 01-Jul-2022 A61B5/4094
To view Neuronostics’s complete patent history, request access »

Neuronostics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neuronostics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel Investors Bristol Angel Group Minority
Ascension Ventures Corporate Venture Capital Minority
British Business Bank Lender/Debt Provider Minority
New Wave Ventures Venture Capital Minority
Epilepsy Foundation of America Corporation
You’re viewing 5 of 18 investors. Get the full list »

Ready to get started?

Request a free trial

Neuronostics FAQs

  • When was Neuronostics founded?

    Neuronostics was founded in 2017.

  • Where is Neuronostics headquartered?

    Neuronostics is headquartered in Bristol, United Kingdom.

  • What is the size of Neuronostics?

    Neuronostics has 20 total employees.

  • What industry is Neuronostics in?

    Neuronostics’s primary industry is Decision/Risk Analysis.

  • Is Neuronostics a private or public company?

    Neuronostics is a Private company.

  • What is Neuronostics’s current revenue?

    The current revenue for Neuronostics is .

  • How much funding has Neuronostics raised over time?

    Neuronostics has raised $6.89M.

  • Who are Neuronostics’s investors?

    Angel Investors Bristol, Ascension Ventures, British Business Bank, New Wave Ventures, and Epilepsy Foundation of America are 5 of 18 investors who have invested in Neuronostics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process